Negron v. Cigna Health and Life Insurance Company et al
Case Number:
3:16-cv-01702
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Dorsey & Whitney
- Izard Kindall
- Keller Rohrback
- Lockridge Grindal
- Milberg Coleman
- Morgan Lewis
- Motley Rice
- Robinson & Cole
- Sarraf Gentile
- Scott&Scott
- Whitfield Bryson
- Zimmerman Reed
Companies
Sectors & Industries:
-
August 18, 2023
Cigna Strikes Deal To Settle ERISA Suit Over Drug Prices
Cigna told a Connecticut federal court Friday that it has agreed to end a proposed class action alleging it violated the Employee Retirement Income Security Act by overcharging health plan participants for pharmacy benefits.
-
March 27, 2023
Cigna Beats RICO Claims In ERISA Drug Prices Suit
A Connecticut federal judge on Monday granted Cigna partial summary judgment in a consolidated class action from health plan participants who alleged they were overcharged for pharmacy benefits, finding participants couldn't demonstrate the insurer violated federal anti-corruption laws through the use of two third-party vendors.
-
May 20, 2021
Cigna Defeats Class Cert. Bid In ERISA Suit Over Drug Prices
Participants in Cigna-administered health plans on Thursday lost their bid to certify a proposed class action accusing the insurer of scheming to overcharge beneficiaries for prescription drugs, with a Connecticut federal judge saying that differences among thousands of health plans make classwide adjudication impossible.
-
September 01, 2020
Cigna Gets Suits Over Drug Prices Pared Down
A Connecticut federal judge has cut state law claims from a suit accusing Cigna and OptumRx of a scheme to overcharge plan participants for prescription drugs, finding that a Georgia county worker didn't show that Cigna was liable to his health plans' beneficiaries.
-
March 13, 2018
Cigna Must Face RICO Claims In Insured Price Suit
A Connecticut federal judge on Monday kept intact the bulk of a putative class action alleging Cigna Health and Life Insurance Co. and others improperly pumped up the price of prescription drugs without informing customers, refusing to dismiss Racketeer Influenced and Corrupt Organizations Act claims against the insurer.